20 results about "Corpus luteum" patented technology

The invention provides a strain of lactobacillus plantarum YS-AG23 with high antioxidant activity, and a rhizoma polygonati and radix angelicae sinensis fermented product obtained by fermenting rhizoma polygonati and radix angelicae sinensis with the strain of lactobacillus plantarum YS-AG23. In a D-galactose induced premature ovarian failure mouse model, the fermentation product can regulate up the levels of antioxidant and stress protection genes SOD2 and HO-1 and an anti-aging gene SIRT1 by regulating down the expression of a key gene AGER of an inflammation and oxidative stress pathway, so that the oxidative stress and inflammatory response of model mouse ovarian tissues are remarkably reduced; meanwhile, the serum hormone level can be specifically adjusted, the serum estradiol (E2) level can be increased, the follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels can be reduced to be close to the normal range, the expression of anti-mullerian hormone (AMH) and hormone regulatory gene LHR of ovarian reserve markers can be up-regulated, the proliferative activity and estrogen secretion function of follicular granulosa cells can be improved, and the effect of preventing ovarian reserve is achieved. The wet weight of atrophic uterus and ovary of the model mouse is remarkably increased, uterine and ovary atrophy is effectively reversed, and the ovarian reserve function of the D-galactose induced premature ovarian failure model mouse is recovered. Besides, in an H2O2-induced human dermal fibroblast aging model, the yeast can improve the activity of aging cells in a concentration-dependent manner and reduce the level of reactive oxygen species (ROS) in the cells; in addition, by up-regulating the expression of a collagen synthesis key gene COL1A1 and down-regulating the expression of a cell senescence marker gene p16, skin cell senescence caused by oxidative stress can be effectively improved. In conclusion, the polygonatum sibiricum and angelica sinensis leavening can synchronously improve premature ovarian failure and skin cell senescence caused by oxidative stress by accurately regulating and controlling oxidative stress, inflammatory response and tissue function related genes, and has wide application potential.

This invention discloses an in vitro maturation culture medium for ferret oocytes and its preparation method, belonging to the field of animal embryo engineering technology. It comprises the following components: TCM199 basal culture medium, 50 mL fetal bovine serum, 25 IU follicle-stimulating hormone, 25 IU luteinizing hormone, 0.5 mg 17β-estradiol, 0.005 mg epidermal growth factor, 12.1 mg sodium pyruvate, 0.2 mM cysteine, 0.1 mM cysteine, 0.030 g penicillin, 0.025 g streptomycin sulfate, as well as an antioxidant complex, a combination of growth factors, and extracellular matrix components. This invention provides a comprehensive and suitable nutritional environment for ferret oocytes by precisely formulating a composite culture medium containing multiple key components. Specifically, the hormone combination at specific concentrations accurately simulates the in vivo physiological environment, effectively regulating the oocyte maturation process; multiple growth factors work synergistically to promote oocyte growth, development, and differentiation; and the addition of the antioxidant complex effectively eliminates free radicals generated during in vitro culture, reducing oxidative stress damage to oocytes.

The invention discloses a pharmaceutical composition for treating corpus luteum insufficiency type infertility as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The technical problem to be solved is to provide the pharmaceutical composition for treating the LPD type infertility, which is simpler in formula, lower in cost and better in treatment effect. According to the technical scheme, the pharmaceutical composition is prepared from the following raw materials: codonopsis pilosula, astragalus membranaceus, fried rhizoma atractylodis macrocephalae, angelica sinensis, semen cuscutae, fried eucommia ulmoides, fried teasel root, honey-fried licorice root, processed radix aconiti carmichaeli and cornu cervi degelatinatum. The pharmaceutical composition provided by the invention can improve ovarian injury, ferroptosis phenomenon, embryo implantation disorder, uterine artery blood perfusion and the like caused by LPD, and is helpful for various pathological problems related to LPD.

The invention belongs to the technical field of biological medicine manufacturing, and particularly relates to a pharmaceutical preparation for improving ovarian functions and a preparation method thereof. The pharmaceutical preparation comprises the following raw materials in parts by weight: 12-25 parts of berberine hydrochloride, 8-16 parts of shionone, 5-10 parts of dicliptera chinensis polysaccharide, 10-20 parts of a diluent, 5-9 parts of an adhesive and 1-6 parts of a lubricant. According to the pharmaceutical composition, berberine hydrochloride, shionone and dicliptera chinensis polysaccharide are compounded, sexual cycle disorder caused by the polycystic ovarian syndrome is adjusted in a synergistic interaction mode, insulin resistance is improved, indexes such as luteinizing hormone (LH), follicle-stimulating hormone (FSH) and LH / FSH are remarkably improved, and the pharmaceutical composition has the application potential of treating the polycystic ovarian syndrome and has good application prospects. And the market prospect is wide.

This invention belongs to the field of biomedical technology, specifically relating to the application of a composition in the preparation of a drug for the prevention and treatment of polycystic ovary syndrome (PCOS). The composition comprises bovine spleen peptide and adenosine; the mass ratio of bovine spleen peptide to adenosine is 1:(1-2.5). Bovine spleen peptide, as a bioactive polypeptide, significantly improves insulin resistance associated with PCOS by targeting and activating the PI3K-Akt signaling pathway and promoting insulin receptor substrate phosphorylation. Adenosine, as a natural bioactive substance, significantly reduces serum luteinizing hormone and testosterone levels in rats and increases follicle-stimulating hormone levels, thereby effectively alleviating hyperandrogenism symptoms such as hirsutism and acne in PCOS. Furthermore, this composition can significantly improve polycystic pathological changes in the ovarian tissue of model rats, reduce the number of cystic dilated follicles, restore the granulosa cell layer structure, alleviate ovarian stromal hyperplasia, and promote normal follicular development.

The invention relates to a traditional Chinese medicine effective component screening method based on a chemical fingerprint spectrum and multi-omics combined analysis. The method comprises the following steps: preparing a semen cuscutae-fructus lycii medicine pair extract and establishing a UPLC-Q-TOF-MS / MS chemical fingerprint spectrum; detecting the levels of estradiol, luteinizing hormone, anti-mullerian hormone and follicle-stimulating hormone in the premature ovarian insufficiency animal model; screening characteristic components related to the drug effect through multivariate statistical analysis; performing transcriptome sequencing on the ovarian tissue, and combining GO / KEGG analysis to determine a key pathway; integrating database prediction targets and differential genes, screening hub genes and constructing a protein interaction network; and finally verifying the binding activity of the candidate component and the core target protein through molecular docking and molecular dynamics experiments. According to the invention, systematic screening and action mechanism analysis of drug effect related components are realized, and a new technical approach is provided for mass marker determination and estrogen simulating action research of the dodder-wolfberry drug pair.

A grading and counting method for follicles and corpus luteum growing in ovaries of rats relates to the technical field of image analysis, and comprises the following steps: scanning ovary staining sections; identifying needed ovarian tissues and converting the needed ovarian tissues into a first region of interest ROI1; screening out growing follicles and corpus luteum meeting requirements on ROI1; and identifying and marking the screened growing follicles meeting the requirements as primary follicles, secondary follicles, tertiary follicles and follicles which cannot be graded, identifying and marking the screened corpus luteum meeting the requirements as newborn corpus luteum, recent corpus luteum, old corpus luteum and corpus luteum which cannot be graded, and finally counting to obtain the number of the follicles and corpus luteum of each level. According to the invention, artificial intelligence of classification and counting of ovarian growth follicles and corpus luteum of rats can be realized, and rapid and accurate batch operation is realized.

The present invention relates to assisted reproductive management technologies common to animal husbandry, more specifically technologies and processes enabling timed artificial insemination (TAI) and timed embryo transfer (TET), superovulation for multiple ovulation embryo transfer (MOET) and superstimulation for ovum pickup (OPU) prior to in-vitro fertilization. More specifically, the present invention is directed to simplified, single-injection methods and formulations to control the onset of estrus and ovulation occurring within the reproductive technologies described above. The formulations focus on progesterone (P4) and luteinizing hormone (LH).

The invention discloses application of cubilose in preparation of a product for improving polycystic ovarian syndrome. The cubilose can effectively improve the hormone level of a patient with the polycystic ovarian syndrome, remarkably improve the levels of follicle-stimulating hormone and estradiol, reduce the levels of luteinizing hormone and testosterone and reduce the ratio of the content of the luteinizing hormone to the content of the follicle-stimulating hormone.

The application belongs to the technical field of aquaculture, and particularly relates to a water temperature-hormone synergistically regulated aquaculture population breeding and hatching method and application. The growth regulator is butyric acid or sodium butyrate. The growth regulator is used to enhance the breeding promotion effect of luteinizing hormone-releasing hormone or its analogs. The breeding promotion refers to promoting the growth of oocytes, promoting yolk accumulation, shortening the ovarian development cycle, and improving the egg production rate. It is found and verified for the first time that butyric acid and its sodium salt can enhance the breeding promotion effect of luteinizing hormone-releasing hormone.

The invention discloses a novel application of a compound MLN4924 (Pevonedat) in preparation of a medicine for improving oocyte quality and treating related diseases, and belongs to the technical field of biological medicines. PCOS animal model experiments prove that the reproductive endocrine indexes of model animals can be remarkably improved by applying the MLN4924, and the reproductive endocrine indexes are specifically represented by restoring the regularity of an estrus cycle and reducing the levels of testosterone and luteinizing hormone in serum; meanwhile, the fertility is improved, and the birth number is increased. In the aspect of oocyte quality, the treatment can increase the number of normal oocytes in an ovary, improve the first polar body discharge rate of in-vitro maturation of the oocytes and improve the blastocyst formation rate after in-vitro fertilization. A further mechanism research shows that the MLN4924 can inhibit the plasmosis of the TRIM21 in the ovarian granular cells and down-regulate the expression level of the protein of the TRIM21. The results show that the MLN4924 provides a new drug choice for developing related diseases for treating polycystic ovarian syndrome (PCOS) and improving oocyte quality.

The invention discloses an application of a sheep placenta extract in preparation of a medicine for improving polycystic ovarian syndrome, and relates to the technical field of biological medicine, the medicine is used for improving endocrine disorder and abnormal inflammation caused by the polycystic ovarian syndrome, and particularly for reducing the plasma androgen level and increasing the plasma estrogen level and the plasma progestational hormone level; the level of an inflammatory factor TNF-alpha is reduced, and the level of an inflammatory factor IL-10 is increased. The sheep placenta extract can improve ovarian polycystic lesions caused by polycystic ovarian syndrome (PCOS) in a targeted manner, and experiments show that after intervention of the sheep placenta extract, the number of macroscopic cystic follicles in rat ovary is reduced, the weight of the ovary with abnormal weight gain is remarkably reduced, the cystic follicle ratio in ovarian histopathology detection is greatly reduced, and the sheep placenta extract has a good application prospect. The ratio of the number of the corpus luteum is closer to normal, and the pathological injury of the polycystic ovarian syndrome is repaired from the organ level.

The invention discloses application of P-G3 in preparation of a medicine for improving fertility of obese women. The invention provides a first double-target treatment new drug P-G3 (third-generation PAMAM) for obese female infertility, which can reverse double injuries of peripheral ovarian fat accumulation and central reproductive axis imbalance (hypothalamic GnRH neuron low activity) at the same time, reduce fat around ovaries in a targeted manner, improve the curative effect of the ovaries, and improve the curative effect of the ovaries. The problems of female follicular dysplasia caused by obesity, low secretion level of luteinizing hormone (LH) and weak reaction of hypothalamus-pituitary axis (HP) to Kisspeptin-54 are obviously improved, and the fertility of obese women is improved.

The utility model discloses a cattle and horse ovary simulation teaching model, which comprises a hard shell used for simulating ovary, an elastic balloon is arranged in the hard shell, a booster pump can inflate gas or liquid into the elastic balloon through a catheter, and after the elastic balloon is expanded, the outer wall of the elastic balloon protrudes through an opening on the wall surface of the hard shell so as to simulate follicles. Meanwhile, a soft outer surface layer is laid on the outer wall of the hard ball body, and protrusions are arranged on the soft outer surface layer to simulate the corpus luteum formed after follicle rupture and ovulation. A connecting body is sleeved on the guide pipe; the connecting body comprises an elastic rod and a hard rod which are nested inside and outside, and the elastic rod is connected with the hard shell, so that the hard shell has two states, namely a movable state when the elastic rod extends out of the hard rod and a fixed state when the elastic rod extends into the hard rod. According to the utility model, after the hard rod is fixed, the sight line of a trainee is separated from the hard shell, so that follicle and corpus luteum identification and palpation training and ovary grasping training can be realized in two states of fixing and moving the ovary position.

The invention discloses a sheep oocyte in-vitro maturation culture solution and a culture method. The sheep oocyte in-vitro maturation culture solution comprises an M199 culture medium, and fetal calf serum with a volume fraction of 10%, a penicillin-streptomycin mixed solution with a volume fraction of 1%, a follicle-stimulating hormone with a volume fraction of 0.02 IU / mL, a luteinizing hormone with a volume fraction of 0.02 IU / mL, 17 beta-estradiol with a volume fraction of 1 [mu] g / mL, cysteine with a volume fraction of 0.1 mmol / L and 13 (S)-HODE with a volume fraction of 200 nmol / L are added into the M199 culture medium. The sheep oocyte in-vitro maturation culture solution contains 13 (S)-HODE, and 13 (S)-HODE can reduce the lipid peroxidation level of sheep oocytes, improve the mitochondrial membrane potential, reduce the oocyte iron ion content, reduce oocyte ferroptosis and improve the blastocyst efficiency after oocyte in-vitro fertilization, can effectively improve the oocyte quality, and can be used for preparing the sheep oocyte in-vitro maturation culture solution. The early embryo development capability is improved.

The invention discloses an excretion promoting cycle hormone trend analysis method and system based on minimally invasive body surface collection. A minimally invasive monitoring patch is attached to the body surface of a patient, a minimally invasive collection structure penetrates through the skin cuticle to obtain skin surface interstitial fluid and related body surface signals, and the obtained body surface minimally invasive collection signals are subjected to baseline calibration, noise elimination and multi-modal feature extraction. And based on the body fluid spectral characteristics, the body surface optical characteristics and the skin electrical characteristics, fusion analysis is carried out to generate change trend results of estradiol, follicle-stimulating hormone, luteinizing hormone and progesterone, and then stage judgment is carried out on the excretion promotion cycle and an analysis result is output. According to the method, on the premise of not entering a dermal vascular layer and not relating to blood sampling operation, continuous analysis of the hormone change trend in the excretion promoting period is achieved, and the method is suitable for an excretion promoting period management scene.

The invention relates to an ovary-targeted fumaric acid-based MOFs (Metal-Organic Frameworks) material as well as a preparation method and application thereof. The ovary-targeted fumaric acid-based MOFs material comprises a cerium fumarate metal organic framework serving as a substrate and luteinizing hormone polypeptide grafted on the surface of the substrate, wherein the luteinizing hormone polypeptide is grafted on the surface of the cerium fumarate metal organic framework through an amide condensation reaction and is used for targeting an ovarian tissue; the mass ratio of the luteinizing hormone polypeptide to the cerium fumarate metal organic framework is (0.05-2): 10; and the particle size of the ovary targeting fumaric acid-based MOFs material is 200 to 400 nm. Compared with the prior art, the ovarian targeting fumaric acid-based MOFs material prepared by the invention has the advantages of simple synthesis process, low cost, easiness in batch production, good treatment effect, excellent biocompatibility, dispersion stability and in-vivo safety, capability of targeting ovarian tissues, capability of retarding oxidative stress and inflammation of focus parts, and wide application prospect. Excellent clinical application prospects are realized in the field of biological medicines.

The application provides a construction method and application of a polycystic ovary syndrome animal model; through a way of intragastric administration, the mouse intestinal tract is transplanted with fusobacterium nucleatum, and through a certain frequency, the fusobacterium nucleatum can be stably planted, and a stable polycystic ovary syndrome symptom is successfully generated; the sex hormone level of the mouse is significantly different from the PCOS characteristic, is shown as the increase of the LH level, the LH / FSH ratio and the T level, and multiple vesicle structures are seen in the ovary, and no mature follicle and corpus luteum are seen, so that the typical symptom of the polycystic ovary syndrome is met, and a new model selection is provided for screening of a treatment drug or experimental research of the polycystic ovary syndrome.

This invention discloses the application of FGA protein in improving egg production in chickens, belonging to the field of genetic engineering technology. Experiments have demonstrated that the FGA gene has a significant effect on improving egg production in chickens. Experimental results show that overexpression of the FGA gene can significantly increase the levels of reproductive hormones such as follicle-stimulating hormone, luteinizing hormone, estradiol, and progesterone in chicken serum, while significantly reducing prolactin concentration. Regarding follicle development, it can significantly increase the number of small yellow follicles, reduce the number of small white follicles, and promote follicle maturation. Regarding lipid metabolism regulation, it can significantly increase the concentrations of cholesterol, triglycerides, and very low-density lipoprotein in serum. This invention reveals for the first time the molecular mechanism by which the liver-specific endocrine factor FGA regulates egg production in chickens through interstitial communication, providing a new molecular target and application strategy for improving egg production in local chicken breeds.

The invention relates to the technical field of biology, in particular to application of cathepsin L and a product for predicting ovulation. According to the present invention, the first research results show that whether ovulation can be accurately determined according to the CTSL concentration in the female mammal body fluid such as urine and / or blood, the ovulation time can be accurately predicted, the accuracy is significantly higher than the luteinizing hormone (LH) determination method, and the method can be widely used for mammal breeding and human ovulation monitoring, fertility control or contraception.